Teens invent refrigerator that doesn't need electricity; aim to help rural communities
Three teens from India created a refrigerator that doesn't need electricity to work.
The Thermavault uses salt to stay cool.
The creators aim to help rural areas that don't have access to electricity.
Three teens from India have created a salt-powered refrigerator and their goal is to help medical facilities in rural areas that don't have access to electricity.
Dhruv Chaudhary, Mithran Ladhania and Mridul Jain are all students at the Shishukunj International School Indore.
Their recent invention, called the Thermavault, was submitted to The Earth Prize which inspires students to solve environmental sustainability problems across the world.
Dig deeper
The Thermavault uses "ionocaloric cooling based on the dissolution enthalpy of ammonium chloride in water to fuel its cooling process," according to the official website.
This type of system will allow whatever is inside the Thermavault to remain cold without the use of electricity, which is a crucial workaround for rural areas.
What they're saying
"The COVID-19 pandemic served as a reminder of the lack of electricity availability in rural areas; we've seen, firsthand, the problems with transporting vaccines, food and essential supplies to these locations. Thus, we redesigned our science-fair cooling system into our solution," the group shared on The Earth Prize website.
What's next
While Chaudhary, Ladhania and Jain did not win the global Earth Prize, they did win the regional competition.
Their inventions won them $12,500 from The Earth Prize and the group plan to use the money to build more Thermavaults, according to Business Insider.
Chaudhary, Ladhania and Jain plan to build 200 more Thermavaults and send them to 120 hospitals for testing.
"We have been able to keep the vaccines inside the Thermavault for almost 10 to 12 hours," Dr. Pritesh Vyas, an orthopedic surgeon who tested the device at V One hospital in Indore, said in a video on the Thermavault website.
The Source
Information for this article was gathered from a Business Insider report, The Earth Prize website and the Thermavault website. This story was reported from Los Angeles.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
43 minutes ago
- Los Angeles Times
Letters to the Editor: ‘The potential of AI to take over our daily life is grossly exaggerated'
To the editor: It would be easy to conclude that contributing writer Matt Lewis is too young to have read the heavyweight press in the 1970s, when the media had just discovered the microchip ('AI will be more disruptive than COVID. Which party can seize the moment?,' Aug. 15). He would have read endless screeds about how many millions would be put out of work, with their skills on the junk heap, agonizing over how we will ever fill these endless hours of leisure. It didn't happen. And yet our memories are so short that again we find acres of newsprint filled with the declarations of pundits telling us that many more millions of jobs will be wiped out by the irresistible power of artificial intelligence. We need to face the fact that the potential of AI to take over our daily life is grossly exaggerated. This is already becoming obvious. Just take note of the number of court cases that have been thrown out because the citations dug up by AI have been nonsense. A major study on children's health promoted by the Department of Health has been shown to be based on references collected by AI that are either nonexistent or fatally flawed. The data on which AI bases its pronouncements is all published information. Much of it is misinformation. The idea that large language models will be able to learn to tell the difference is pie in the sky. Rory Johnston, HollywoodThis writer is a co-author of the 1985 book 'The Knowledge Machine: Artificial Intelligence and the Future of Man.'
Business Wire
an hour ago
- Business Wire
ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA ® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a significant public health challenge with no currently available established therapies. The new study, called COVID-4.019-Long, further expands the company's clinical research efforts to assess ANKTIVA's potential beyond cancer or cancer-related diseases. Currently, ANKTIVA is being evaluated alone and with other agents in multiple studies for different forms of bladder cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin lymphoma, Lynch syndrome, ovarian cancer and Human Papillomavirus (HPV) associated tumors. ANKTIVA is also being studied in Human Immunodeficiency Virus (HIV) and lymphopenia. The primary objective of the exploratory, single-arm study (NCT0712372 7) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA's ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells. 'We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the case with coronaviruses in general. But we now know viral nucleic acid and proteins can be in the gut mucosa months after infection. As such, an antiviral strategy looks insufficient to treat or cure long COVID. Based on clinical insights to date, we believe ANKTIVA may be a new therapeutic option for this chronic and potentially disabling condition by enhancing immune function, facilitating viral clearance, and addressing underlying contributions to long COVID.' The study, which is being conducted by ImmunityBio and aims to recruit up to 40 participants who meet the long COVID criteria, as established by the World Health Organization (WHO), is now accepting patients for initial screening to determine study eligibility. The safety and tolerability of ANKTIVA for long COVID is also being assessed in a separate Phase 2 study conducted at the University of California – San Francisco. Both studies are supported by ImmunityBio. To learn more, visit ANKTIVA is currently approved by the U.S. Food and Drug Administration with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. About Long COVID Long COVID is a serious illness that can cause chronic health conditions requiring comprehensive care. It may also lead to disability. 2 Long COVID impacts approximately 1 in 5 Americans adults who had a previous COVID-19 infection. 1 It can include a wide range of ongoing symptoms and conditions that can last weeks, months, or even years after COVID-19 illness. 1 Some of the common among the more than 200 identified symptoms include fatigue, brain fog, coughing, shortness of breath, heart palpitations and change in smell or taste. 3 Anyone who had a SARS-CoV-2 infection, the virus that causes COVID-19, can experience Long COVID, including children. 1 Long COVID remains a significant public health challenge with no currently available established treatments. About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. A key component in the company's BioShield platform, ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Prescribing Information for ANKTIVA ® at References: Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. May 3 2023;76(9):1636-1645. U.S. Centers for Disease Control and Prevention. Long COVID Basics. July 2025. Available at U.S. Centers for Disease Control and Prevention. Long COVID Signs and Symptoms. July 2025. Available at About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the potential health conditions associated with Long COVID, potential patient populations and implications thereof, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.
Yahoo
an hour ago
- Yahoo
Ukraine's electronic warfare fight against Russian drones is so chaotic that its own are getting caught in the crossfire
Russia and Ukraine are desperately trying to stop each others' drones using electronic warfare. Soldiers sometimes accidentally jam their own sides' drones if they're on the same frequency. There are so many drones that soldiers can be confused about which side they belong to. With too many drones in the air and only so many radio frequencies, Ukrainian soldiers sometimes accidentally jam their own drones trying to stop Russian ones, Business Insider learned. Dimko Zhluktenko, a drone operator with Ukraine's Unmanned Systems Forces who has operated strike and reconnaissance drones, told Business Insider that his unit was recently the victim of friendly electronic warfare, or just EW. He said it's something that often happens with the big reconnaissance drones that both sides use because many of Ukraine's drones "use the same frequencies that enemy drones use." That's been the case, for instance, with Russia's Zala recon and strike drones and Ukraine's Shark reconnaissance drones. "When friendly EW tries to jam Zala, it also jams Shark," he said. Ukraine uses the Shark to identify targets that other Ukrainian weaponry can then destroy, including Russian artillery convoys, and Russia uses its Zala to identify Ukrainian targets and attack Ukrainian assets like tanks and artillery. The Shark drone is developed by Ukrainian company Ukrspecsystems, and its newest version has a range of 260 miles, while the Zala is made by Russia's Zala Aero. The huge volume of drones used in Russia's invasion of Ukraine has resulted in an electronic warfare battle, with jamming and more flooding frequencies with noise, cutting connections, and confusing enemy drones, frustrating operators attempting to use them for strikes and surveillance. It's fueled new developments in EW, as well as efforts to get around electronic warfare, such as fiber-optic drones and AI-enabled systems. Zhluktenko said there are so many drones in the sky that Ukrainian soldiers have to try to coordinate when they fly drones, to try to avoid the accidental jamming of their own side's drones. In a single one-mile stretch of the front line, there might be more than 60 drones in the sky, he said. In his area, a roughly three-mile section, there might be around three large Russian reconnaissance drones in flight at any given time. There's a lot of other stuff in the air though, and that can make it hard to tell what belongs to which side. Zhluktenko previously told BI that it can be so difficult to tell the drones apart that infantry soldiers sometimes panic and jam everything with their electronic warfare systems. He said: "They literally click all of the frequencies to be jammed because they're scared." Another Ukrainian drone operator, who previously spoke to BI on the condition of anonymity, said the confusion sometimes causes soldiers to try to shoot down every drone they see. As Western militaries look to adopt small drones in new ways, concerns about battlefield confusion are a priority. Combat footage from Ukraine has shown troops frantically questioning if the drone buzzing overhead is on their side. With some dropping grenades or screaming out of the sky and exploding, soldiers may have only moments to sort that out. Drone usage is higher in this war than in any other conflict in history. Among these systems are the more traditional large reconnaissance drones, emerging small strike drones, and drones with weaponry like firearms and grenades. These weapons are designed to attack and gather information on the enemy and guide other weapons and combat forces. The prolific employment of drone technology has sparked an innovation race between Russia and Ukraine to create new types of drones and drone technologies. On both sides, domestic innovation and defense engineering are fueling developments, as is support from foreign partner nations. Ukraine is relying on drones as it faces Russia's far-larger military and deals with shortages in Western-provided weaponry. Drones are something that Ukraine can make itself in large quantities, with efforts ranging from huge companies to small outfits in people's garages. It's a key part of Ukraine's growing domestic defense industry, which also includes homegrown missiles, air defense systems, and ground robots. Ukraine said it made 2.2 million drones last year, and it aims to make four million this year. But Russia also sees value in drones and is investing heavily in boosting output. It uses them at the front lines, as well as to complicate its strike packages when targeting Ukrainian cities, mixing one-way attack drones with missiles. The huge volume of drones has led to some irregularities in battle, such as panic jamming. It's also resulted in drone operators sometimes accidentally being able to see each other's drone feeds, allowing them to unintentionally pick up intelligence about what enemy drones are doing and collecting. There are just so many drones and only so many operating frequencies that drone feeds can get switched without them doing anything. Ukrainian and Russian troops are working through these issues in real time, and lessons learned from the fight may shape future wars. Read the original article on Business Insider
